OBJECTIVE: To systematically evaluate the efficacy and safety of Xingnaojing injection combined with Shuxuetong injection in the treatment of cerebral infarction. METHODS: PubMed

the Cochrane Library

Web of Science

EMBase

CBM

VIP database

CNKI and Wanfang database were retrieved to collect the randomized controlled trial of Xingnaojing injection combined with Shuxuetong injection in the treatment of cerebral infarction（ the study group was treated with Xingnaojing injection combined with Shuxuetong injection

while the control group received conventional regimen

Shuxuetong injection

Shuxuetong injection combined with calf blood or sodium aescinate combined with citicoline treatment）

the retrieval time was from the establishment of the database to Oct.2020. After the quality assessment and data extraction of included literature

RevMan 5. 3 statistical software was used for Meta-analysis. RESULTS: A total of 9 literature were included

all of which were randomized controlled trials

with a total of 706 patients. Meta-analysis showed that the total effective rate（ OR = 3. 96

P < 0. 000 01） and cure rate（ OR= 2. 20

P < 0. 000 01） in the study group were significantly better than those in the control group

and the mortality rate（ OR = 0. 28

P = 0. 03） and neurological deficit scores（ MD =-4. 45

P < 0. 000 01） in the study group were significantly lower than those in the control group

with statistically significant differences. There was no statistically significant difference in the incidence of adverse drug reactions between two groups（ P = 0. 24）. CONCLUSIONS: The efficacy of Xingnaojing injection combined with Shuxuetong injection in the treatment of cerebral infarction is better than that of the control regimens（ conventional regimen

Shuxuetong injection

Shuxuetong injection combined with calf blood or sodium aescinate combined with citicoline treatment）

the two are equivalent in terms of safety. However

due to the lower quality of included literature and the small sample size

the results still need to be further confirmed by large-scale

multi-center clinical randomized controlled trials.